Enhancement of Anticancer Effects by Combining 5-Fluorouracil with Refametinib in Human Oral Squamous Cell Carcinoma Cell Line

Enhancement of Anticancer Effects by Combining 5-Fluorouracil with Refametinib in Human Oral Squamous Cell Carcinoma Cell Line

(1) Background: Oral squamous cell carcinoma (OSCC) is a significant health burden worldwide. This study aimed to determine the potentials of Refametinib, an orally bioavailable selective MEK1/2 inhibitor, to increase the effectiveness of 5-Fluorouracil (5-FU), a common cytotoxic drug, in the SCC4 c...

Full description

Bibliographic Details
Main Authors: Po-Chun Chen, Bor-Chyuan Su, Tien-Li Ma, Ying Chui Hong, Yu-Wen Chen, Thi Thuy Tien Vo, Luo-Yun Wu, Tzu-Yu Peng, Ching-Shuen Wang, I-Ta Lee
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Applied Sciences
Subjects:
5-fluorouracil
apoptosis
extracellular signal-related kinase
MEK inhibitor
oral squamous cell carcinoma
programmed death-ligand 1
Online Access:https://www.mdpi.com/2076-3417/13/7/4340

Internet

https://www.mdpi.com/2076-3417/13/7/4340

Similar Items